Raymond James Maintains Outperform on Catalyst Biosciences, Lowers Price Target to $18
Raymond James analyst Steven Seedhouse maintains Catalyst Biosciences (NASDAQ:CBIO) with a Outperform and lowers the price target from $19 to $18.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Catalyst Biosciences Q2 EPS $(0.64) Up From $(0.96) YoY, Sales $1.13M Down From $1.66M YoY
Catalyst Biosciences (NASDAQ:CBIO) reported quarterly losses of $(0.64) per share. This is a 33.33 percent increase over losses of $(0.96) per share from the same period last year. The company reported $1.13 million in
Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA
The FDA has granted Fast Track Designation to Catalyst Biosciences Inc’s (NASDAQ:CBIO) Marzeptacog alfa (activated), MarzAA, the Company’s subcutaneously administered next-generation engineered…
Catalyst Biosciences Q1 EPS $(0.79) Down From $(0.28) YoY, Sales $1.47M Down From $16.37M YoY
Catalyst Biosciences (NASDAQ:CBIO) reported quarterly losses of $(0.79) per share. This is a 182.14 percent decrease over losses of $(0.28) per share from the same period last year. The company reported $1.47 million in